BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26842107)

  • 1. Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial.
    Tallon D; Wiles N; Campbell J; Chew-Graham C; Dickens C; Macleod U; Peters TJ; Lewis G; Anderson IM; Gilbody S; Hollingworth W; Davies S; Kessler D
    Trials; 2016 Feb; 17():66. PubMed ID: 26842107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
    Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
    Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
    BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.
    Duffy L; Clarke CS; Lewis G; Marston L; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Mangin D; Moore M; Nazareth I; Wiles N; Bacon F; Bird M; Brabyn S; Burns A; Donkor Y; Hunt A; Pervin J; Lewis G
    Health Technol Assess; 2021 Nov; 25(69):1-62. PubMed ID: 34842135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol.
    Furukawa TA; Akechi T; Shimodera S; Yamada M; Miki K; Watanabe N; Inagaki M; Yonemoto N
    Trials; 2011 May; 12():116. PubMed ID: 21569309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.
    Banerjee S; Hellier J; Romeo R; Dewey M; Knapp M; Ballard C; Baldwin R; Bentham P; Fox C; Holmes C; Katona C; Lawton C; Lindesay J; Livingston G; McCrae N; Moniz-Cook E; Murray J; Nurock S; Orrell M; O'Brien J; Poppe M; Thomas A; Walwyn R; Wilson K; Burns A
    Health Technol Assess; 2013 Feb; 17(7):1-166. PubMed ID: 23438937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial.
    Duffy L; Bacon F; Clarke CS; Donkor Y; Freemantle N; Gilbody S; Hunter R; Kendrick T; Kessler D; King M; Lanham P; Lewis G; Mangin D; Marston L; Moore M; Nazareth I; Wiles N; Lewis G
    Trials; 2019 Jun; 20(1):319. PubMed ID: 31159856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.
    Lewis G; Duffy L; Ades A; Amos R; Araya R; Brabyn S; Button KS; Churchill R; Derrick C; Dowrick C; Gilbody S; Fawsitt C; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Khan N; Lanham P; Pervin J; Peters TJ; Riozzie D; Salaminios G; Thomas L; Welton NJ; Wiles N; Woodhouse R; Lewis G
    Lancet Psychiatry; 2019 Nov; 6(11):903-914. PubMed ID: 31543474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMBINED MIRTAZAPINE AND SSRI TREATMENT OF PTSD: A PLACEBO-CONTROLLED TRIAL.
    Schneier FR; Campeas R; Carcamo J; Glass A; Lewis-Fernandez R; Neria Y; Sanchez-Lacay A; Vermes D; Wall MM
    Depress Anxiety; 2015 Aug; 32(8):570-9. PubMed ID: 26115513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primary care: the THREAD (THREshold for AntiDepressant response) study.
    Kendrick T; Chatwin J; Dowrick C; Tylee A; Morriss R; Peveler R; Leese M; McCrone P; Harris T; Moore M; Byng R; Brown G; Barthel S; Mander H; Ring A; Kelly V; Wallace V; Gabbay M; Craig T; Mann A
    Health Technol Assess; 2009 Apr; 13(22):iii-iv, ix-xi, 1-159. PubMed ID: 19401066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial.
    Wiles N; Thomas L; Abel A; Barnes M; Carroll F; Ridgway N; Sherlock S; Turner N; Button K; Odondi L; Metcalfe C; Owen-Smith A; Campbell J; Garland A; Hollinghurst S; Jerrom B; Kessler D; Kuyken W; Morrison J; Turner K; Williams C; Peters T; Lewis G
    Health Technol Assess; 2014 May; 18(31):1-167, vii-viii. PubMed ID: 24824481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
    Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
    Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial.
    Rifkin-Zybutz R; MacNeill S; Davies SJ; Dickens C; Campbell J; Anderson IM; Chew-Graham CA; Peters TJ; Lewis G; Wiles N; Kessler D
    J Psychopharmacol; 2020 Dec; 34(12):1342-1349. PubMed ID: 33143538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategic use of new generation antidepressants for depression: SUN(^_^) D protocol update and statistical analysis plan.
    Yonemoto N; Tanaka S; Furukawa TA; Kato T; Mantani A; Ogawa Y; Tajika A; Takeshima N; Hayasaka Y; Shinohara K; Miki K; Inagaki M; Shimodera S; Akechi T; Yamada M; Watanabe N; Guyatt GH;
    Trials; 2015 Oct; 16():459. PubMed ID: 26466684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment resistant depression in primary care: the CoBalT randomised controlled trial protocol.
    Thomas LJ; Abel A; Ridgway N; Peters T; Kessler D; Hollinghurst S; Turner K; Garland A; Jerrom B; Morrison J; Williams C; Campbell J; Kuyken W; Lewis G; Wiles N
    Contemp Clin Trials; 2012 Mar; 33(2):312-9. PubMed ID: 22101205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mirtazapine versus other antidepressive agents for depression].
    Knud Larsen J
    Ugeskr Laeger; 2012 Nov; 174(46):2864-6. PubMed ID: 23153468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis.
    Watanabe N; Omori IM; Nakagawa A; Cipriani A; Barbui C; McGuire H; Churchill R; Furukawa TA;
    CNS Drugs; 2010 Jan; 24(1):35-53. PubMed ID: 20030418
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.